Epic Sciences Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 94

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 21

Epic Sciences General Information

Description

Developer of diagnostic tests technology intended for quick and non-invasive detection of genetic and molecular changes in cancer throughout. The company's technology assesses the number of circulating tumor cells and their subtypes, profiles single-cell phenotype and genotype as well as provide near real-time information about each different cellular population before and after treatments with no cell left behind, enabling oncologists to identify and analyze rare disease cells from a tube of blood that also contains millions of normal cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Decision/Risk Analysis
Corporate Office
  • 9381 Judicial Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Epic Sciences Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epic Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Secondary Transaction - Private 01-Apr-2023 00000 Completed Generating Revenue
15. Later Stage VC (Series G) 27-Feb-2023 0000 00000 00000 Completed Generating Revenue
14. Later Stage VC (Series F) 29-Apr-2022 0000 00000 00000 Completed Generating Revenue
13. Secondary Transaction - Private 01-Feb-2021 00000 Completed Generating Revenue
12. Debt - PPP 14-Apr-2020 00.000 00000 Completed Generating Revenue
11. Later Stage VC (Series E) 12-Sep-2018 0000 00000 00000 Completed Generating Revenue
10. Debt - General 01-Aug-2017 0000 00000 Completed Generating Revenue
9. Later Stage VC (Series D) 28-Apr-2017 0000 00000 0000 Completed Generating Revenue
8. Later Stage VC (Series C1) 23-May-2016 $6.74M $69M 000.00 Completed Generating Revenue
7. Debt - General 01-Jun-2015 $15M $62.3M Completed Generating Revenue
To view Epic Sciences’s complete valuation and funding history, request access »

Epic Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series G-2 0,000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series G-1 0,000,000,000 00.000000 00 00.00 00.00 00 00.00 00
To view Epic Sciences’s complete cap table history, request access »

Epic Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of diagnostic tests technology intended for quick and non-invasive detection of genetic and molecular changes
Biotechnology
San Diego, CA
94 As of 2024
00000
00000000000 00000

000000

ectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
0000000000 000000000
Beverly, MA
00 As of 0000
00.00
00000 00000

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000000000 000000000
Austin, TX
000 As of 0000
000.00
00000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epic Sciences Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genomic Expression Venture Capital-Backed Beverly, MA 00 00.00 00000 00000
Asuragen Formerly VC-backed Austin, TX 000 000.00 000000&0 000.00
Adaptive Biotechnologies Formerly VC-backed Seattle, WA 000 00000 00000000 00000
Menarini Silicon Biosystems Formerly VC-backed Castel Maggiore, Italy 00000 000.00 000000&0 000.00
Agena Bioscience Formerly PE-Backed San Diego, CA 000 0000 000000&0 0000
You’re viewing 5 of 32 competitors. Get the full list »

Epic Sciences Patents

Epic Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230175073-A1 Enhanced characterization of breast cancer Pending 07-Dec-2021 0000000000
US-20220260574-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000 0
AU-2018275265-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000
EP-3631445-A1 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 000000000000
EP-3631445-A4 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease Pending 02-Jun-2017 G01N33/57434 0
To view Epic Sciences’s complete patent history, request access »

Epic Sciences Executive Team (22)

Name Title Board Seat
W. Lloyd Sanders President, Chief Executive Officer & Board Member
Mark Aguillard Chief Commercial Officer
Peter Kuhn Ph.D Co-Founder & Chief Scientific Advisor
Jorge Nieva Co-Founder
Richard Wenstrup MD Chief Medical Officer
You’re viewing 5 of 22 executive team members. Get the full list »

Epic Sciences Board Members (13)

Name Representing Role Since
Andrew ElBardissi MD Deerfield Management Board Member 000 0000
Charles Kennedy MD Blue Ox Healthcare Partners Board Member 000 0000
Gregory Lucier Self Chairman 000 0000
James Rothman Ph.D Arsenal Capital Partners Board Member 000 0000
Kim Kamdar Ph.D Domain Associates Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Epic Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epic Sciences Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arsenal Capital Partners PE/Buyout Minority 000 0000 000000 0
ATEM Capital Venture Capital Minority 000 0000 000000 0
Blue Ox Healthcare Partners Growth/Expansion Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Labcorp Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

Epic Sciences FAQs

  • When was Epic Sciences founded?

    Epic Sciences was founded in 2008.

  • Who is the founder of Epic Sciences?

    Peter Kuhn Ph.D, Jorge Nieva, Steven French, and Dena Marrinucci Ph.D are the founders of Epic Sciences.

  • Who is the CEO of Epic Sciences?

    W. Lloyd Sanders is the CEO of Epic Sciences.

  • Where is Epic Sciences headquartered?

    Epic Sciences is headquartered in San Diego, CA.

  • What is the size of Epic Sciences?

    Epic Sciences has 94 total employees.

  • What industry is Epic Sciences in?

    Epic Sciences’s primary industry is Biotechnology.

  • Is Epic Sciences a private or public company?

    Epic Sciences is a Private company.

  • What is Epic Sciences’s current revenue?

    The current revenue for Epic Sciences is 000000.

  • How much funding has Epic Sciences raised over time?

    Epic Sciences has raised $243M.

  • Who are Epic Sciences’s investors?

    Arsenal Capital Partners, ATEM Capital, Blue Ox Healthcare Partners, Deerfield Management, and Labcorp Venture Fund are 5 of 21 investors who have invested in Epic Sciences.

  • Who are Epic Sciences’s competitors?

    Genomic Expression, Asuragen, Adaptive Biotechnologies, Menarini Silicon Biosystems, and Agena Bioscience are some of the 32 competitors of Epic Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »